BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-06 pm EST			5-day change	1st Jan Change
121.72 ^USD	+2.42%		+2.81%	+15.33%

Dec. 06	European Equities Traded in the US as American Depositary Tread Water in Friday Trading	MT
Dec. 06	Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024	CI

BIONTECH : Deutsche Bank reiterates its Buy rating

November 27, 2024 at 07:38 am EST

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. The target price continues to be set at USD 150.

Latest news about BioNTech SE

European Equities Traded in the US as American Depositary Tread Water in Friday Trading	Dec. 06	MT
Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024	Dec. 05	CI
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading	Nov. 27	MT
BIONTECH : Deutsche Bank reiterates its Buy rating	Nov. 27	ZD
BIONTECH : Goldman Sachs maintains a Buy rating	Nov. 26	ZD
BIONTECH : Jefferies maintains a Buy rating	Nov. 26	ZD
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week	Nov. 22	MT
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	Nov. 21	MT
US CDC expects COVID and RSV levels to increase in coming weeks	Nov. 20	RE
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading	Nov. 19	MT
Trump-induced Pharma fears shouldn't be long-lived	Nov. 19
Evercore ISI Upgrades BioNTech SE to Outperform	Nov. 19	MT
Berenberg Initiates BioNTech at Buy With $130 Price Target	Nov. 19	MT
BIONTECH : Upgraded to Buy by Berenberg	Nov. 19	ZD
BIONTECH : Goldman Sachs reiterates its Buy rating	Nov. 18	ZD
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week	Nov. 15	MT
BIONTECH : JP Morgan sticks Neutral	Nov. 15	ZD
Futures drop as Powell signals no hurry on rate cuts	Nov. 15	RE
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department	Nov. 15	DJ
Germany's BioNTech to Buy China-based Biotheus in Oncology Push	Nov. 15	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Nov. 14	MT
BioNTech SE - Special Call	Nov. 14
BIONTECH : Goldman Sachs maintains a Buy rating	Nov. 14	ZD
European Equities Close Slightly Lower in Wednesday Trading; Eurozone Business Outlook Declines	Nov. 13	MT
European Equities Traded in the US as American Depositary Fall in Wednesday Trading	Nov. 13	MT

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Employees

6,133

Sector

Biotechnology & Medical Research

Calendar

2024-12-09 - San Antonio Breast Cancer Symposium

More about the company